Список литературы

2687-0940

Challenges in modern medicine

2687-0940

CARDIOLOGY

<strong>The role of osteoprotegerin as a predictor of cardiovascular events in patients with metabolic syndrome and diabetes mellitus (review)</strong>

Golivets

Tatyana P.

Golivets

Tatyana P.

golivets@ya.ru

Gagarina

Diana O.

Gagarina

Diana O.

ya.diana-art@yandex.ru

Dubonosova

Diana G.

Dubonosova

Diana G.

ya.diana-art@yandex.ru

Likrizon

Sergey V.

Likrizon

Sergey V.

likrizonendo@mail.ru

2021

44100

The review reveals the importance of osteoprotegerin for the development and progression of the atherosclerotic process. In connection with its participation in the processes of cardiac and vascular remodeling and the formation of calcification of vascular smooth muscle cells, its role as a possible predictor of adverse cardiovascular events in patients with metabolic syndrome and type 2 diabetes mellitus is discussed. Osteoprotegerin as a biomarker indicating inflammation of adipose tissue data are presented, and a direct correlation between its plasma level and insulin resistance is established. The value of quantitative indicators of osteoprotegerin as marker of «silent» myocardial ischemia in patients with diabetes mellitus was analyzed. Effect of medicinal and non-medicinal methods of treatment on the circulating level of osteoprotegerin data are presented. The expediency of determining the quantitative index of osteoprotegerin as an indicator of the development of atherosclerosis in the early stages of occurrence, as well as a diagnostic and prognostic marker of cardiovascular pathology in patients with metabolic syndrome and diabetes mellitus was studied. Taking into account inconsistency of many of the findings in the studies, it is determined that further studies are necessary to obtain new evidence about the diagnostic and prognostic value of osteoprotegerin in the development of cardiovascular pathology, including in patients with metabolic syndrome and diabetes mellitus.

osteoprotegerinpredictorcardiovascular diseasesobesitymetabolic syndromediabetes mellitusinsulin resistance

Список литературы

Barabanova N.A. 2015. Rol' adipokinov i osteoprotegerinav razvitii ateroskleroza i serdechno-sosudistogo remodelirovaniya u bol'nyh saharnym diabetom 2 tipa [The role of adipokines and osteoprotegerins in the development of atherosclerosis and cardiovascular remodeling in patients with type 2 diabetes mellitus]. Abstract. dis. ... cand. med. sciences. Samara 22.

Vavilova T.P., Pleten’ A.P., Mikheev R.K. 2017. Biologicheskaya rol' adipokinov kak markerov patologicheskih sostoyanij [Biological role of adipokines and their association with morbid conditions]. Voprosy pitaniia [Problems of Nutrition]. 86 (2): 5–13.

Verbovoi A.F., Akimova D.V., Verbovaia N.I. 2014 Sostoianie mineralnoi plotnosti kostnoi tkani i pokazateli kostnogo metabolizma u zhenshchin s sakharnym diabetom 2-go tipa [The state of bone mineral density and bone metabolism indicators in women with type 2 diabetes mellitus]. Endocrinology: news, opinions, training. 1 (5): 39–43.

Verbovoy A.F., Tsanava I.A., Mitroshina E.V. 2017. Osteoprotegerin novyi marker serdechno-sosudistykh zabolevanii [Osteoprotegerin is a new marker of cardiovascular diseases]. Therapeutic archive. 4: 91–94.

Verbovoi A.F., Sharonova L.A., Verbovaia N.I., Akimova D.V. 2014 Soderzhanie vitamin D3 i pokazateli metabolizma kostnoi tkani u muzhchin s sakharnym diabetom 2-go tipa [Vitamin D3 content and bone metabolism indicators in men with type 2 diabetes mellitus]. Osteoporosis and osteopathies. 1: 8–10.

Gratchev A.N., Samoilova D.V., Rashidova M.A. Petrenco A.A., Kovaleva O.V. 2018. Makrofagi, associirovannye s opuhol'yu: sovremennoesostoyanie issledovanij i perspektivy klinicheskogo ispol'zovaniya [Tumor associated macrophages: current research and perspectivesof clinical use]. Uspekhi molekulyarnoy onkologii. 5 (4): 20–28.

Kapralova I.Yu., Verbovoj A.F. 2015. Uroven` osteoprotegerina i nekotory`x adipokinov pri gipotireoze [The level of osteoprotegerin and certain adipokins in hipothyroidism]. Klinicheskaya medicina. 93 (3): 48–52.

Muromceva G.A. Koncevaya A.V., Konstantinov V.V., Artamonova G.V., Gatagonova T.M., Duplyakov D.V., Efanov A.Yu., Zhernakova Yu.V., Il'in V.A., Konradi A.O., Libis R.A., Minakov E.V., Nedogoda S.V., Oshchepkova E.V., Romanchuk S.V., Rotar' O.P., Trubacheva I.A., Deev A.D., Shal'nova S.A., Chazova I.E., Shlyahto E.V., Bojcov S.A., Balanova Yu.A., Gomyranova N.V., Evstifeeva S.E., Kapustina A.V., Litinskaya O.A., Mamedov M.N., Metel'skaya V.A., Oganov R.G., Suvorova E.I., Hudyakov M.B., Baranova E.I., Kasimov R.A., Shabunova A.A., Ledyaeva A.A., Chumachek E.V., Azarin O.G., Babenko N.I., Bondarcov L.V., Furmenko G.I., Hvostikova A.E., Belova O.A., Nazarova O.A., Shutemova E.A., Barbarash O.L., Danil'chenko Ya.V., Indukaeva E.V., Maksimov S.A., Mulerova T.A., Skripchenko A.E., Cherkass N.V., Basyrova I.R., Isaeva E.N., Kondratenko V.Yu., Lopina E.A., Safonova D.V., Gudkova S.A., Cherepanova N.A., Kaveshnikov V.S., Karpov R.S., Serebryakova V.N., Medvedeva I.V., Storozhok M.A., Shava V.P., Shalaev S.V., Gutnova S.K., Tolparov G.V. 2014. Rasprostranennost' faktorov riska neinfekcionnyh zabolevanij v rossijskoj populyacii v 2012–2013 gg. Rezul'taty issledovaniya ESSE-RF [Prevalence of risk factors for noncommunicable diseases in the Russian population in 2012–2013 The research results of the ESSE-RF.] Cardiovascular therapy and prevention. 13 (6): 4–11.

Tepliakov A.T., Berezikova E.N., Shilov S.N., Popova A.A. 2018. Osteoprotegerin novyi nezavisimyi prediktor progressirovaniia khronicheskoi serdechnoi nedostatochnosti assotsiirovannoi s sakharnym diabetom 2-go tipa i osteoporozom [Osteoprotegerin is a new independent predictor of the progression of chronic heart failure associated with type 2 diabetes mellitus and osteoporosis]. Bulletin of Siberian Medicine. 17 (4): 141–151.

Berezin A. 2016. Bone-Related Proteins as Markers in Vascular Remodeling. In: Preedy V.R., Editor. Biomarkers in Bone Disease. Berlin: Springer. 1–22.

Bernardi S., Fabris B., Thomas M., Toffoli B., Tikellis C. Cand ido R., Catena C., Mulatero P., Barbone F., Radillo O. 2014. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol. Cell. Endocrinol., 394: 13–20.

Bernardi S., Bossi F., Toffoli B., Fabris B. 2016. Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease. Biomed. Res. Int. 2016; 1752854.

Çağlar S., Çağlar A., Pilten S., Albay C., Beytemur O., Sarı H. 2018. Eklem Hastalik Cerrahisi. 29 (3): 170–175.

Davenport C., Harper E., Forde H., Rochfort K.D., Murphy R.P. 2016. RANKL promotes osteoblastic activity in vascular smooth muscle cells by upregulating endothelial BMP-2 release. Int. J. Biochem. Cell. Biol. 77: 171–180.

Erol M., Bostan Gayret O., Tekin Nacaroglu H. 2016. Iran Red. Crescent. Med. J. 18 (11). doi: 10.5812/ircmj.41873. [PMID: 28203453].

Fuernau G., Poenisch C., Eitel I., de Waha S., Desch S. 2014. Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial. Eur. J. Heart. Fail. 16: 880–887.

Garvey W.T, Mechanick J.I., Brett E.M., Garber A.J., Hurley D.L., Jastreboff A.M., Nadolsky K., Pessah-Pollack R., Plodkowski R. 2014. American association of Clinical Endocrinologists and American college of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 20 (9): 977–989.

Hosbond S.E., Diederichsen A.C., Saaby L., Rasmussen L.M., Lambrechtsen J. 2014. Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings? Atherosclerosis. 236: 230–236.

Huang S.J., Wang H.W., Wu H.F. 2020. Osteoprotegerin, interleukin and hepatocyte growth factor for prediction of diabetes and hypertension in the third trimester of pregnancy World Journal of Clinical Cases. 8 (22): Pages 5529–5534.DOI: 10.12998/wjcc.v8.i22.5529.

Karavanaki K., Tsouvalas E., Vakaki M. 2018. Pediatr. Endocrinol. Metab. 31 (11): 1169–1177. doi: 10.1515/jpem-2018-0147.

Kemperman H., Schrijver I.T., Roest M., Kesecioglu J., Solinge W.W., Lange D.W. 2019. Osteoprotegerin is higher in Sepsis than in Noninfectious SIRS and Predicts 30-Day Mortality of SIRS Patients in the Intensive Care. The Journal of Applied Laboratory Medicine. 3 (4): 559–568.

Kotanidou E., Kotanidis C., Giza S. 2018. Endocr. Res. 7: 1–7. doi:10.1080/07435800.2018.1480630.

Margonato A., Gorla R., Macchi A., Buzzetti F., Franzoni I. 2015. Role of plaque calcification regulators osteoprotegerin and matrix Gla-proteins instable angina and acute myocardial infarction. J. Cardiovasc. Med. (Hagerstown). 16: 156–162.

Mozos Ioana. 2017. Osteoprotegerin and myocardial infarction. Myocardial infarction. 5: 2–27.

Musialik K., Szulińska M., Hen K. Skrypnik D., Bogdanski P. 2017. The relation between osteoprotegerin, inflammatory processes, and atherosclerosis in patients with metabolic syndrome. European Review for Medical and Pharmacological Sciences; 21: 4379–4385.

O'Sullivan E.P., Ashley D.T., Davenport C. 2013. A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance. Metabolism: Clinical and Experimental. 1: 34–38.

Oz H., Gavish D., Hass A., Shargorodsky M. 2015. Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS. J. Renin. Angiotensin. Aldosterone. Syst. 16: 547–52.

Peng Duan, Min Yang, Meilin Wei, Jia Liu. 2017. International Journal of Endocrinology. 2: 8–15.

Perez de Ciriza C., Lawrie A., Varo N. 2015. Osteoprotegerin in Cardiometabolic Disorders. Int. J. Endocrinol., 2015: 564934.

Suliburska J., Bogdanski P., Gajewska E., Kalmus G., Sobieska M. and Samborski W. 2013. The association of insulin resistance with serum osteoprotegerin in obese adolescents. Journal of Physiology and Biochemistry. 4: 847–853.

Tavintharan S., Pek L.T., Liu J.J., Ng X.W., Yeoh L.Y. 2014. Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus. Diab. Vasc. Dis. Res., 11: 359–362.

Thaman R.G., Arora G.P. 2013. Metabolic Syndrome: Definition and Pathophysiology– the discussion goes on! J. Phys. Pharm. Adv. 3(3): 48–56. DOI: 10.5455/jppa.20130317071355.

Uzui H., Morishita T., Nakano A. 2014. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. Journal of Cardiovascular Pharmacology and Therapeutics. 36: 304–309.

Zampetti S., Lucantoni F., Pacifico L. 2019. J. Endocrinol. Invest. 42 (4): 427–434. doi: 10.1007/s40618-018-0932-y.